Pharmacology/Pharmaceutical Industry
Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.
18 Jan, 2022 | 09:41h | UTC
Association of hormonal contraceptive use with adverse health outcomes: an umbrella review of meta-analyses of randomized clinical trials and cohort studies.
18 Jan, 2022 | 09:29h | UTC
WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.
17 Jan, 2022 | 00:48h | UTCNews release: WHO recommends two new drugs to treat COVID-19 – World Health Organization
Infographic with the updated recommendations: A living WHO guideline on drugs for covid-19 – The BMJ
Commentaries:
Commentary on Twitter (thread – click for more)
WHO has also conditionally recommended the use of sotrovimab for treating mild or moderate #COVID19 in patients who are at high risk of hospitalization: patients who are older, immunocompromised, with underlying conditions & those unvaccinated https://t.co/UAc21Wgxbl https://t.co/Z39mSKrOv5
— World Health Organization (WHO) (@WHO) January 14, 2022
Viewpoint: COVID-19 therapeutics for nonhospitalized patients.
17 Jan, 2022 | 00:31h | UTCCOVID-19 Therapeutics for Nonhospitalized Patients – JAMA
Editorial: Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management – JAMA
RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.
16 Jan, 2022 | 23:13h | UTCThe D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Related:
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
Research: Circulating vitamin D concentration and risk of seven cancers
Research: Vitamin D and risk of total and site specific cancers
RCT: Vitamin D supplementation is not beneficial for the prevention of cardiovascular disease and cancer.
16 Jan, 2022 | 23:11h | UTCNews Release: Five years of high-dose vitamin D did not affect incidence of cardiovascular disease or cancer – University of Eastern Finland
Related:
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
Research: Circulating vitamin D concentration and risk of seven cancers
Research: Vitamin D and risk of total and site specific cancers
RCT: Ketamine induced remission in 46% of patients but was NOT non-inferior to electroconvulsive therapy for the treatment of hospitalized patients with unipolar depression.
16 Jan, 2022 | 23:01h | UTCNews Release: ECT more effective than ketamine in severe depression – Lund University
Commentary on Twitter
RCT-OL: 63% of inpatients with MDD receiving ECT remitted vs. 46% receiving ketamine infusions (p=0.026). Both ketamine and ECT required a median of 6 sessions to induce remission. Long-lasting AE include persisting amnesia with ECT https://t.co/tvJ0qwUu62 pic.twitter.com/NOQK8Xv8TW
— PfOL (@psychopharmacol) December 12, 2021
Perspective: Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age.
16 Jan, 2022 | 22:53h | UTCCommentaries:
Researchers urge: ‘Prescribe aspirin based on benefit-to-risk not age’ – Florida Atlantic University
Preventive Aspirin Should Be Based on Benefit, Not Age – HealthDay
Cluster randomized trial: no added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis.
16 Jan, 2022 | 22:59h | UTC
Unvaccinated pregnant people are at higher risk for Covid complications and newborn deaths.
14 Jan, 2022 | 08:44h | UTCUnvaccinated pregnant people are at higher risk for Covid complications and newborn deaths – STAT
Original Study: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland – Nature Medicine
COVID vaccines safely protect pregnant people: the data are in.
14 Jan, 2022 | 08:43h | UTCCOVID vaccines safely protect pregnant people: the data are in – Nature
Related:
COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm.
Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.
AstraZeneca vaccination not linked to reduced fertility rates and adverse birth outcomes.
Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.
5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.
CDC Guidance: Pregnant people should be vaccinated against COVID-19.
Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.
Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.
14 Jan, 2022 | 08:37h | UTCFluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario
Related:
Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.
Commentary on Twitter
Thinking of prescribing fluvoxamine for covid 19? Ontario has a nice infographichttps://t.co/MKT8PqlJpM
— Todd Lee (@DrToddLee) January 12, 2022
RCT: In patients with Parkinson disease uncontrolled with Levodopa, MAO-B inhibitors or dopamine agonists as adjuvant therapies were associated with better patient-rated quality of life compared to COMT inhibitors.
14 Jan, 2022 | 08:15h | UTC
Commentary on Twitter
In poorly controlled #ParkinsonDisease, study found adding a COMT inhibitor to existing treatment is not as good as adding a MAOB inhibitor or dopamine agonist https://t.co/0GrA2YYMbI pic.twitter.com/d4VNnom2zk
— JAMA Neurology (@JAMANeuro) December 28, 2021
Systematic Review: Ketamine for the treatment of mental health and substance use disorders.
14 Jan, 2022 | 08:08h | UTCCommentaries:
Ketamine therapy swiftly reduces depression and suicidal thoughts – University of Exeter
Ketamine May Quickly Ease Tough-to-Treat Depression – HealthDay
Phase 2 RCT: In patients with generalized pustular psoriasis, Spesolimab improved lesions at one week but was associated with infections and systemic drug reactions.
14 Jan, 2022 | 08:01h | UTCTrial of Spesolimab for Generalized Pustular Psoriasis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Trial of Spesolimab for Generalized Pustular Psoriasis – Mount Sinai
Systematic Review: In patients with intermittent claudication, Propionyl‐L‐carnitine may improve walking distance when compared to placebo (moderate overall certainty of evidence).
14 Jan, 2022 | 08:02h | UTCPropionyl‐L‐carnitine for intermittent claudication – Cochrane Library
Summary: Propionyl-L-carnitine for intermittent claudication – Cochrane Library
RCT: In patients with immune-mediated inflammatory diseases (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis) treated with Infliximab, a proactive therapeutic drug monitoring protocol was more likely to lead to sustained disease control.
14 Jan, 2022 | 07:57h | UTCEffect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentary on Twitter
Study found proactive therapeutic drug monitoring (TDM) compared with treatment without TDM during maintenance infliximab therapy was more likely to lead to sustained disease control over 52 weeks for patients with immune-mediated inflammatory diseases https://t.co/yfJjyADaOT pic.twitter.com/JtOfQxFFDS
— JAMA (@JAMA_current) December 21, 2021
Observational study in adolescents showed the Pfizer-BioNTech vaccine had an overall effectiveness of 94% against hospitalization and 98% against critical Covid-19.
13 Jan, 2022 | 09:00h | UTCEditorial: Sparing of Severe Covid-19 in Vaccinated Adolescents – New England Journal of Medicine
Study shows COVID-19 vaccines offer lasting protection against hospitalization and death.
13 Jan, 2022 | 09:01h | UTCNews Release: Study shows COVID-19 vaccines offer lasting protection – University of North Carolina at Chapel Hill
An observational study in South Africa estimates the Pfizer vaccine had an effectiveness of 70% against hospitalization for Covid-19 caused by the omicron variant.
13 Jan, 2022 | 08:56h | UTCCommentary: BNT162b2 still effective, but less so, against Omicron – HealthDay
RCT: Early Remdesivir in outpatients can prevent progression to severe Covid-19.
13 Jan, 2022 | 08:54h | UTCEditorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right?
Commentary: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress
Commentary on Twitter
Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. #COVID19 #IDTwitter https://t.co/YFflw5nBxB pic.twitter.com/4NCD9AcnYH
— NEJM (@NEJM) December 22, 2021
Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized.
13 Jan, 2022 | 08:48h | UTCInvited Commentary: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
RCT: A single dose of a novel adenovirus type 5 vectored SARS-CoV-2 vaccine was safe and had 57.5% efficacy against symptomatic Covid-19 and 91.7% efficacy against severe disease in adults.
13 Jan, 2022 | 08:44h | UTCCommentaries:
Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine – The Lancet
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
13 Jan, 2022 | 08:17h | UTCThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin – Drugs
Statement on therapies for high-risk, nonhospitalized patients with mild to moderate Covid-19.
12 Jan, 2022 | 09:14h | UTCSee also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines